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ABSTRACT  
Objectives: Although Quality-Adjusted Life Years (QALYs) are increasingly being used by 
decision makers to make comparisons of cost-effectiveness, there are no otological-specific 
outcome measures that fit within this QALY framework.  This study had two main objectives.  
The first was to provide a means to derive QALYs from a condition-specific otological 
instrument (COQOL) and the second, was to assess the convergent validity, or degree of 
correlation, between the COQOL and SF-6D, an established QALY instrument. 
Design: Longitudinal cohort study designed to assess the convergent validity between SF-6D 
and COQOL, and to generate a mapping function to enable SF-6D values to be predicted 
from the COQOL responses. 
Setting: Cambridge University Hospital, UK 
Participants: 207 patients attending a routine outpatient general otology clinic. 
Main outcome measures: SF-6D and the COQOL instrument completed at baseline, and 
again 3 months later. 
Results: Convergent validity was demonstrated with mean SF-6D values decreasing linearly 
with increasing severity on the COQOL instrument.  Overall, the correlation between the 
COQOL scores and the SF-6D values was moderate and statistically significant (r=.490, 
p=<0.001).  A simple mapping model based on an Ordinary Least Squares regression 
function predicted SF-6D values from the COQOL data with a reasonable degree of accuracy.  
Further validation using the follow up 3-month data confirmed the prediction power of this 
mapping model. 
Conclusions: This study provides a method for estimating QALYs from condition-specific 
COQOL data and provides the opportunity for the cost-effectiveness of otological treatment 
to be measured and placed within the national QALY framework.  
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Health care resources are scarce and difficult decisions are required to allocate expenditure 
in a manner that is both efficient and equitable. To enable the assessment of the merits of 
alternative treatment options across different clinical areas, a common unit of health 
outcome is required, and in the UK, decision making bodies such as the National Institute of 
Health and Care Excellence (NICE) recommend the use of the Quality-Adjusted Life Year 
(QALY)1. 
 
QALYs are constructed by combining information on length of life with an index value 
representing a person’s health-related quality of life (HRQOL) on a cardinal scale with death 
(0) and full health (1) denoting either end of the scale. Thus a person’s ‘QALY-expectancy’ is 
the life expectancy ‘adjusted’ for the quality of life experienced.  For example, if a person 
has an index value for HRQOL equal to 0.5, and 10 years left to live, then the QALY-
expectancy is equal to 5 QALYs (10*0.5). If treatment improves the index value for HRQOL 
to 0.6 or extends life by 2 years, the QALY-expectancy would increase to 6 (0.6*10, or 
0.5*12), and the QALY gain attributable to treatment under both scenarios would be 1 
QALY.  Overtime, the use of QALYs as a decision making tool has increased and is now used 
to inform resource allocation decisions worldwide2.   
 
Generic preference-based instruments have been designed to generate index values for the 
estimation of QALYs, such as the EQ-5D3 or the SF-6D4. Generic instruments are applied 
across a range of conditions, allowing decision makers to compare the return in health 
outcomes for investments in different clinical areas on a common scale.  These instruments 
are completed by patients and describe their current health state on the domains covered 
by the instrument: this combination of domain scores is known as their health profile. Each 
health profile in a preference-based measure has an index value attributed to it, which 
represents the preferences of a sample of respondents (usually a general population 
sample) for different health profiles. The final index value reflects a weighting of the 
domains within the instruments, for example ‘pain’ might be weighted more than ‘self-care’, 
and it is this preference-based weighting that makes HRQOL index values distinct from 
general HRQOL scores. 
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It is generally regarded as good practice for clinical studies to use condition-specific HRQOL 
instruments as these have been developed to be relevant to the patient population5. While 
well-designed condition-specific HRQOL instruments should provide a more sensitive 
response to ill-health than generic instruments, it is rare that these instruments are 
preference-based due to the extensive research required to generate the index value sets. 
Furthermore, condition-specific HRQOL instruments would not allow comparison of the 
value gains in HRQOL on the common metric needed by decision-making bodies such as 
NICE who consider health care interventions for a wide range of conditions.  
 
In the absence of preference-based condition specific instruments, and recognising the need 
to measure outcomes using QALYs, techniques such as ‘mapping’ or ‘cross-walking’ can be 
used to predict index values from responses to condition-specific instruments6.  A 
regression-based algorithm or a mapping function is used to allow index values to be 
predicted.  The predictive quality of the algorithm depends on the conceptual overlap of the 
two instruments (condition-specific and preference-based).  It is therefore important to 
assess the convergent validity of both instruments by exploring the degree to which 
domains are related.    
 
The Cambridge Otology Quality of Life (COQOL) instrument is a newly developed condition-
specific measure for patients with otological conditions7, designed to be completed at 
routine outpatient appointments by patients who self-identify as having ‘ear problems’.  To 
place this instrument into a national framework where QALYs are routinely used to assess 
cost-effectiveness, this paper reports on a study that ‘mapped’ from COQOL to a 
preference-based instrument (the SF-6D). The aims of the study were: 1) to assess the 
convergent validity of the COQOL and the SF-6D instrument; and 2) to construct a mapping 
algorithm to allow QALYs to be generated from COQOL data.  
 
 
METHODS  
Ethical considerations 
This study was devised within the University of Birmingham Health Economics Department 
to complement the COQOL study. Ethical approval was granted by the Cambridge Central 
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Ethics Committee and the Cambridge University Hospitals Research and Development 
Department.   
 
Cambridge Otology Quality of Life Instrument (COQOL)  
The COQOL addresses the range of symptoms experienced by patients with otological 
conditions.  It measures quality of life with respect to ear disease and is designed to be 
completed by patients attending outpatient appointments. Comprising 24 items it address 
specific aural and auditory symptomatology (hearing in different circumstances, tinnitus, 
aural discharge, ear discomfort and pain) and more general quality of life fields such as self-
image, inter-personal relationships and illness-behaviour. Patients are asked to rate a series 
of statements on a 10-point scale where 0 denotes ‘strongly disagree’ and 10 denotes 
‘strongly agree’.  Each item score is added to produce an overall index score that ranges 
from 0 to 240.  Overall, the lower the COQOL score then the better the quality of life. 
 
Short-Form-36 Instrument (SF-36) and the SF6D  
The SF-36 is a non-preference-based generic HRQOL instrument that has 36 questions 
covering 8 dimensions: physical functioning, role-physical, bodily pain, general health, 
vitality, social functioning, role-emotional and mental health8. The SF-6D is a preference-
based health state classification system that is used to derive index values from the SF-36 
instrument.  Responses to six dimensions: physical functioning, role limitations (physical and 
emotional), bodily pain, vitality, social functioning, and mental health are used, and index 
values derived using a published algorithm generated from a general population sample4.     
The range of index values for the SF-6D is 0.301 to 1.00, where 1 indicates full health and 0 
is death.    
 
Both the COQOL and the SF-36 instruments were completed by 207 patients attending a 
routine otology clinic at Cambridge University Hospital, UK, and then again by post 3 months 
later.  For all patients, information on age, sex, and primary pathology was collected.   
 
Analysis 
To assess the relationship between the COQOL dimensions and the SF-6D, the mean SF-6D 
score for different levels of response on the COQOL was examined, with the expectation 
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that increasing scores on each COQOL dimension (an increase in reported problems) would 
be associated with a lower mean SF-6D index value. For this analysis, we grouped COQOL 
response options into the following categories: 0-3 to reflect patients who strongly 
disagreed with the statement; 4-7 to reflect patients who were indifferent to the statement; 
and 8-10 to reflect patients that strongly agreed with the statement.  Convergent validity 
was assessed by comparing the SF-6D mean values using a one-way ANOVA test.  
Furthermore, to visualise the correlation between the instruments a scatter plot of the SF-
6D index values and the overall COQOL score was generated, and the correlation coefficient 
calculated using the Spearman’s rho statistic. 
 
We then explored the mathematical model that most accurately predicted the SF-6D index 
values from the COQOL questions by applying a linear regression with the SF-6D acting as 
dependent variable6.  The first model focused on all questions within the COQOL, the 
second model replicated this, plus ‘squared terms’ to account for non-linearities in the 
variables.  In both cases we used a backward selection process with statistical significance 
set at the 10% level9 to select the best subset of COQOL questions to predict the SF-6D.  
SPSS version 20 was used for all statistical analysis. 
 
 
Internal and external validation 
It is good practice with any mapping exercise to test for the internal validity of the mapping 
models by predicting scores from within the sample, and comparing to observed values.  We 
assessed the models on the basis of the Mean Squared Error (MSE) which is the mean of the 
squared differences between observed and predicted SF-6D values, and the Mean Absolute 
Error (MAE), the mean of absolute differences between observed and predicted SF-6D 
values10.  The lower the MSE and MAE, the better the model is at predicting the index 
values.   
 
To assess the external validity of the mapping models we used the data from the follow-up 
phase (at 3 months).  Due to drop out this dataset contained 77 patients.  To observe how 
accurately the models predict index values we ran the models and then compared the 
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predicted and observed index values.    The same performance criteria from the internal 
validation exercise were then applied to this external dataset.    
 
 
RESULTS 
The mean age of the 207 patients in the sample at baseline was 51 years (SD 18 years) and 
51% (n=105) were female. The primary pathology of the patients was stable (22%) or active 
(14%) chronic suppurative otitis media (CSOM), vertigo (14%), hearing loss (13%), tinnitus 
(8%), otsclerosis (7%), otitis externa (7%), wax (7%), Eustachian tube dysfunction (2%), or 
some other ontological condition (6%). An SF-6D index value could be generated for 189 
(91%) of the sample, and the mean value was 0.71 (SD 0.11). The mean COQOL score 
(available for all patients at baseline) was 84.8 (SD 43.6). The distribution of both measures 
appeared approximately normal, although the SF-6D had a slight positive skew, whilst the 
COQOL had a slight negative skew, both toward the better quality of life end of the scale 
(Figure 1).   
Figure 1 about here 
 
Convergent validity 
In 18/24 COQOL questions, as expected, the mean SF-6D values decreased linearly with 
increasing severity on the COQOL instrument, and this effect was statistically significant at 
the 5% level (table 1).   So in these cases, the more that patients reported problems (values 
8-10) using the COQOL instrument, the greater the negative impact on the mean SF-6D 
values.  This result suggests convergent validity for these particular COQOL questions.  Of 
interest, the negative impact on mean SF-6D values appeared to be greatest from reported 
problems with tinnitus, balance, pain, social life and happiness. Hearing problems seemed 
to affect the SF-6D values the least.   
Table 1 about here 
 
Figure 2 shows the scatter plot between the SF-6D index values and the COQOL scores.  The 
distribution of COQOL values is much wider relative to the distribution of SF-6D as very few 
patients reported SF-6D values below 0.45.  As expected there was a slight negative 
relationship with higher SF-6D values corresponding to lower COQOL scores. 
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Figure 2 about here 
 
Overall, the correlation between the COQOL scores and the SF-6D values showed a 
moderate and statistically significant negative correlation (r = .490, p=<0.001). 
 
The models 
Table 2 shows the results for the OLS models for the prediction of the SF-6D values.  
According to the statistical measures (the adjusted R-squared), model 2 performed better 
than model 1. 
Table 2 about here 
 
Taking the results of model 1 as the simplest case, the following algorithm can be applied to 
COQOL data to generate index values: 
 
SF6D index value =  0.788 + (0.010 * COQOL Q2) + (-0.008 * COQOL Q5) + (-0.011 * 
COQOL Q11) + (-0.008 * COQOL Q14) + (0.008 * COQOL Q15) + (-
0.010 * COQOL Q21) + (-0.009 * COQOL Q24) 
 
Internal and external validation 
Table 3 displays the performance criteria for models 1 and 2 by assessing the difference 
between the predicted versus actual SF-6D values for the baseline sample (internal 
validation), and then the same again for the follow-up 3 month sample (external validation).      
 
Table 3 about here 
 
Both models perform well in the baseline dataset (internal test), predicting mean SF-6D 
values that are the same as the actual mean values. The MAE and MSE statistics also suggest 
that there is no difference in prediction power between the two models.   In the context of 
the range of scores for the SF-6D (0.699; 0.301 – 1), the MAE of 0.072 to 0.079 is an average 
prediction error of 10-11% of the total scale of the SF-6D. Within the external dataset, both 
SF-6D and COQOL data were available for 77 patients at the 3-month time point. At this 
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follow-up the mean COQOL score was 80.8 (SD 48.1) and the SF-6D was 0.70 (SD 0.11).  
Again, both models performed well by predicting mean SF-6D values that are the same, or 
very close to, the actual SF-6D value.  Again, in terms of prediction power measured by the 
MAE and MSE there was little difference between the models, although the MAE and MSE 
were closer in the internal and external validation sets for Model 1, suggesting a better 
model fit. The relationship between the predicted and actual SF-6D for the follow up sample 
is displayed in figure 3.    
Figure 3 about here 
 
 
 
DISCUSSION  
Synopsis of key findings 
This study has demonstrated convergent validity between the condition-specific COQOL 
instrument and the SF-6D preference-based instrument, and assessed how accurately SF-6D 
index values can be predicted from COQOL patient data. It has shown that a mapping model 
can predict SF-6D mean values with a low prediction error and can be used with a 
reasonable degree of accuracy to predict QALYs from the COQOL instrument.   
 
Comparison with other studies 
The COQOL instrument is a newly developed instrument so there are no published mapping 
studies to compare our results.  We can however compare the predictive power of model 1 
to other models that have been published predicting SF-6D mean index values for a patient 
population from condition specific instruments.  The R2 of 0.35 and 0.38 for models 1 and 2 
respectively, is in the range of R2 values reported for condition specific to generic 
instruments in a recent review of mapping studies6. Our results concord with what has been 
reported in the literature that moving to more complex model specifications such as models 
that include squared terms add little to the prediction power, and it is the simpler OLS 
models that on balance perform the best.   
 
Strengths and weaknesses of the study 
This is the first study to apply mapping techniques to a condition-specific otolaryngological 
quality of life instrument and provides a unique opportunity for QALYs to be generated from 
SF6D utility (ordered according to severity 
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COQOL otological-specific patient data. Hitherto, economic analyses of otolaryngological 
interventions have been limited because of the need for data that is required to measure 
QALYs 11. 
 
One drawback of the study was the sample as although typical of patients who present at 
general otology clinics, the numbers were relatively small and ideally a separate patient 
sample should have been used for the external validation.  Instead the best data available 
was used and future research can replicate this analysis on a separate patient sample to 
further assess the prediction power of the mapping algorithm. COQOL and SF-6D values also 
indicated that the sample used in this study had relatively high HRQOL so ideally the 
performance of the algorithm needs further validation for use in populations with greater 
HRQOL impairments.  
 
Clinical applicability of the study 
For decision makers interested in the cost-effectiveness of otological treatments, this study 
presents a mapping algorithm to generate mean SF-6D index values from COQOL data and is 
therefore useful where no generic preference-based data exists but QALY outcomes are 
beneficial. However, although mapping offers a means to generate QALYs, it should always 
be viewed as a second-best option to collecting preference-based measures, such as the SF-
6D, which allow index values to be generated directly from patient responses.   
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Table 1: Mean SF-6D index value by each level of COQOL question 
 
COQOL Questions Level  N Mean SF6D score 
(SD) 
P* 
1) I struggle to hear what people are saying to 
me. 
0 - 3 
4 – 7 
8 – 10 
51 
84 
52 
0.72 (0.12) 
0.71 (0.12) 
0.68 (0.11) 
.353 
2) If I’m in a group of more than 3 people, I 
find it hard to follow the conversation. 
0 - 3 
4 – 7 
8 – 10 
55 
60 
71 
0.71 (0.12) 
0.69 (0.12) 
0.71 (0.11) 
.647 
3) I find it hard to tell if a car is coming 
towards me or going away from me. 
0 - 3 
4 – 7 
8 – 10 
93 
56 
40 
0.71 (0.11) 
0.69 (0.12) 
0.69 (0.12) 
.561 
4) Music doesn’t sound clear or natural to me. 0 - 3 
4 – 7 
8 - 10 
86 
74 
29 
0.72 (0.11) 
0.69 (0.11) 
0.67 (0.12) 
.066 
5) People around me have told me that I turn 
the TV or radio up too loud. 
0 - 3 
4 – 7 
8 - 10 
50 
47 
88 
0.71 (0.12) 
0.73 (0.11) 
0.68 (0.11) 
.048 
6) I struggle to use the telephone 0 - 3 
4 – 7 
8 – 10 
88 
61 
35 
0.73 (0.11) 
0.67 (0.12) 
0.69 (0.11) 
.032 
7) Tinnitus keeps me awake at night 
 
0 - 3 
4 – 7 
8 – 10 
117 
36 
30 
0.72 (0.10) 
0.69 (0.13) 
0.64 (0.12) 
.004 
8) My tinnitus makes it difficult for me to 
follow a conversation in background noise. 
0 - 3 
4 – 7 
8 – 10 
113 
37 
30 
0.72 (0.10) 
0.68 (0.13) 
0.66 (0.12) 
.023 
9) I am bothered by my tinnitus during the 
day-time. 
0 - 3 
4 – 7 
8 – 10 
114 
35 
30 
0.73 (0.11) 
0.67 (0.11) 
0.65 (0.13) 
.002 
10) Sometimes I feel so dizzy that I can’t do 
anything at all. 
0 - 3 
4 – 7 
8 – 10 
128 
24 
31 
0.73 (0.10) 
0.64 (0.12) 
0.65 (0.13) 
.000 
11) My daily activities are limited by my 
balance. 
0 - 3 
4 – 7 
8 – 10 
138 
31 
15 
0.73 (0.10) 
0.64 (0.12) 
0.58 (0.12) 
.000 
12) I am troubled by clicking and popping 
sounds in my ears. 
0 - 3 
4 – 7 
8 – 10 
120 
35 
27 
0.72 (0.10) 
0.68 (0.13) 
0.65 (0.12) 
.010 
13) My ears (or ear) feel blocked. 0 - 3 
4 – 7 
8 – 10 
71 
49 
65 
0.73 (0.11) 
0.72 (0.12) 
0.67 (0.11) 
.002 
14) My ears (or ear) are painful. 0 - 3 
4 – 7 
8 – 10 
111 
52 
22 
0.73 (0.10) 
0.69 (0.11) 
0.61 (0.14) 
.000 
15) I suffer from smelly discharge from my 
ears. 
0 - 3 
4 – 7 
8 – 10 
142 
18 
25 
0.71 (0.11) 
0.72 (0.13) 
0.68 (0.12) 
.427 
16) I am embarrassed by my ear discharge. 0 - 3 
4 – 7 
8 – 10 
142 
16 
20 
0.72 (0.10) 
0.68 (0.15) 
0.69 (0.11) 
.254 
17) I often need to visit the doctor about my 
ears. 
0 - 3 
4 – 7 
8 – 10 
96 
44 
42 
0.73 (0.10) 
0.67 (0.14) 
0.69 (0.10) 
.015 
18) I often feel unwell because of my ears. 0 - 3 114 0.74 (0.10) .000 
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4 – 7 
8 – 10 
40 
32 
0.68 (0.12) 
0.61 (0.12) 
19) My work or other responsibilities are 
affected by my problems with my ears. 
0 - 3 
4 – 7 
8 – 10 
92 
38 
55 
0.74 (0.10) 
0.72 (0.10) 
0.64 (0.11) 
.000 
20) I feel that my ear problems affect my 
concentration. 
0 - 3 
4 – 7 
8 – 10 
95 
46 
45 
0.75 (0.10) 
0.67 (0.11) 
0.64 (0.11) 
.000 
21) I feel limited in my social life because of my 
ear problems. 
0 - 3 
4 – 7 
8 – 10 
104 
40 
43 
0.74 (0.10) 
0.67 (0.12) 
0.64 (0.11) 
.000 
22) I often feel unhappy because of my ear 
problems. 
0 - 3 
4 – 7 
8 – 10 
85 
52 
49 
0.75 (0.10) 
0.68 (0.11) 
0.66 (0.11) 
.000 
23) My ear problems affect how I spend my 
leisure time. 
0 - 3 
4 – 7 
8 – 10 
97 
42 
46 
0.75 (0.10) 
0.67 (0.12) 
0.63 (0.10) 
.000 
24) My ear problems have affected my sense of 
taste. 
0 - 3 
4 – 7 
8 – 10 
134 
31 
17 
0.73 (0.10) 
0.63 (0.13) 
0.62 (0.10) 
.000 
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Table 2: Mathematical models for predicting SF6D index values 
 
 OLS 
 (1) (2) 
COQOL questions: 
I find it hard to follow the conversation (Q2) 
I turn the TV or radio up too loud (Q5) 
My daily activities are limited by my balance (Q11) 
My ears (or ear) are painful (Q14) 
I suffer from smelly discharge from my ears (Q15) 
I feel limited in my social life (Q21) 
My ear problems have affected my sense of taste (Q24) 
I often need to visit the doctor about my ears (Q17) 
 
COQOL questions squared: 
I turn the TV or radio up too loud (Q5) 
My ears (or ear) are painful (Q14) 
I suffer from smelly discharge from my ears (Q15) 
I often need to visit the doctor about my ears (Q17) 
I feel limited in my social life (Q21) 
 
Constant 
 
0.010 
-0.008 
-0.011 
-0.008 
0.008 
-0.010 
-0.009 
- 
 
 
- 
- 
- 
- 
- 
 
0.788 
 
 
0.011 
- 
-0.010 
- 
- 
- 
-0.010 
-0.017 
 
 
-0.001 
-0.001 
0.001 
0.002 
-0.001 
 
0.777 
 
R-squared 
Adjusted R-squared 
0.383 
0.356 
0.419 
0.383 
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Table 3: Performance of models 
 Internal validation External validation 
 Model 1 Model 2 Model 1 Model 2 
 
SF-6D: Actual, mean (SD) 
 
SF-6D: Predicted, mean (SD) 
 
0.71 (0.12) 
 
0.71 (0.07) 
 
 
0.71 (0.12) 
 
0.71 (0.08) 
 
0.70 (0.11) 
 
0.71 (0.08) 
 
0.70 (0.11) 
 
0.70 (0.09) 
MAE* 
MSE* 
0.072  
0.008 
0.072 
0.008 
0.073 
0.008 
0.079 
0.010 
Predictions within 0.1 and 0.05 of observed values: 
0.05 
0.1 
 
44% 
78% 
 
44% 
77% 
 
50% 
76% 
 
43% 
71% 
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Figure 1: Histogram of COQOL and SF-6D data for the baseline sample 
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Figure 2 Scatter plot of COQOL scores and SF-6D values at baseline (first wave) 
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Figure 3: Follow up observed and predicted SF6D values for model 1 and model 2 
 
 
 
 
SF-6D state ordered according to severity 
